Abstract
The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandin-resistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Aminopyridines / pharmacology*
-
Aminopyridines / therapeutic use
-
Animals
-
Antifungal Agents / pharmacology*
-
Antifungal Agents / therapeutic use
-
Candida albicans / drug effects*
-
Candidiasis, Invasive / drug therapy*
-
Caspofungin
-
Dose-Response Relationship, Drug
-
Drug Resistance, Fungal
-
Echinocandins / pharmacology
-
Echinocandins / therapeutic use
-
Fluconazole / pharmacology
-
Fluconazole / therapeutic use
-
Isoxazoles / pharmacology*
-
Isoxazoles / therapeutic use
-
Lipopeptides
-
Male
-
Mice
-
Mice, Inbred ICR
-
Microbial Sensitivity Tests
Substances
-
APX001A
-
Aminopyridines
-
Antifungal Agents
-
Echinocandins
-
Isoxazoles
-
Lipopeptides
-
Fluconazole
-
Caspofungin